Catalyst Wire Dossier Catalyst Wire Dossier

Patidegib topical gel 2%

patidegib · Sol-Gel Technologies, Ltd.
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Patidegib topical gel 2%, covering 2024-07-03 to 2026-07-21. Get the full timeline:

Most recent: Clinical Trial Results: A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC [Phase 2]

See pricing